---
title: "GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293973164.md"
description: "GeoVax Labs reported Q2 2026 results with $0 revenue and a net loss of $4.43M, an 17.6% improvement year-over-year. The company discontinued GEO-CM04S1 to focus on lead vaccine GEO-MVA, advancing to Phase 3 per EMA advice, and Gedeptin for HNSCC. Manufacturing modernization efforts continue via a continuous avian cell line. With the prior BARDA contract terminated, GeoVax relies on equity financings and grants."
datetime: "2026-07-27T20:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293973164.md)
  - [en](https://longbridge.com/en/news/293973164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293973164.md)
generator: "portal-rs"
---

# GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary

GeoVax Labs, Inc. reported results for the 2026 quarter showing no revenue and a reduced net loss versus the prior-year period as the company shifts focus to its lead vaccine and oncolytic programs.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$0

$852.28K

(100%)

Net income²

($4.43M)

($5.37M)

17.6%

Diluted EPS³

($0.97)

($8.74)

88.9%

*¹ Reported as “Revenue from government contract”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per common share”.*

**Business Highlights**

-   GEO‑MVA: Advancing to Phase 3 per EMA advice with a target start in late 2026 to address global orthopox vaccine supply.
-   Portfolio reprioritization: Discontinued GEO‑CM04S1 to concentrate resources on GEO‑MVA and the oncolytic candidate Gedeptin.
-   Gedeptin development: Completed Phase 1/2 in head and neck squamous cell carcinoma (HNSCC); planning a Phase 2 neoadjuvant combination study targeting 2027 initiation.
-   Manufacturing modernization: Developing a continuous avian cell line for scalable cGMP MVA production to improve yield and responsiveness.
-   Revenue & funding: No product sales this quarter; prior BARDA contract was terminated and the company is relying on equity financings and grants for funding.

Original SEC Filing: GeoVax Labs, Inc. \[ GOVX \] - 10-Q - Jul. 27, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md)
- [GOVXW.US](https://longbridge.com/en/quote/GOVXW.US.md)

## Related News & Research

- [What does Europe’s AI lag mean for the region?](https://longbridge.com/en/news/296510589.md)
- [GEO Group director Lindsay L. Koren disposes of 3,500 common shares worth $109,567.50](https://longbridge.com/en/news/296140893.md)
- [Exyn Technologies, Inc. GAAP EPS of -$1.55 misses by $0.95, revenue of $0.95M beats by $0.27M](https://longbridge.com/en/news/296399261.md)
- [GGEO: Q2 2026 saw 7% revenue growth, strong EMEA gains, and improved EBITDA margin to 6.7%](https://longbridge.com/en/news/296576784.md)
- [MWC: Strong growth, global expansion, and new platform launches drive future prospects](https://longbridge.com/en/news/296371778.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**